AR and prostate carcinoma: To further verify the effect of the AR and MAPK/ERK signalling pathways on FEN1 expression in prostate cancer, AR was knocked down and the MAPK/ERK kinase (MEK) inhibitor U0126 was implemented in 22Rv1 and LNCaP cells.